Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rengalin for cough in COPD
NCT03159091Phase 4Completed
- Sponsor
- Materia Medica Holding
- Start
- Jun 2017
- Primary completion
- Apr 2019
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Rengalin in chronic obstructive pulmonary disease (COPD), sponsored by Materia Medica Holding. Primary endpoint: Percentage of Patients With a Positive Treatment Response at 4 weeks. Started Jun 2017; status: completed.
02
Drugs
Rengalin
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03159091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03159091.